NASDAQ OMX

GLOBAL INFRASTRUCTURE PARTNERS III ANNOUNCES AGREEMENT TO ACQUIRE 100% OF EQUIS ENERGY ALONGSIDE PSP INVESTMENTS AND CIC CAPITAL

Dela

New York, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Global Infrastructure Partners ("GIP"), a leading independent global infrastructure investor, announced today that its fund, Global Infrastructure Partners III -- in conjunction with the Public Sector Pension Investment Board ("PSP Investments"), one of Canada's largest pension investment managers, CIC Capital Corporation ("CIC Capital") and a group of its other Limited Partner Co-Investors -- has agreed to acquire 100 percent of the equity interests in the wind and solar renewable energy portfolio of Equis Funds Group ("Equis Energy") for USD3.7 billion.

Equis Energy is one of the largest renewable energy independent power producers in the Asia-Pacific region ("APAC"). Equis Energy is headquartered in Singapore and operates in several of the largest and fastest-growing renewable markets in APAC, including Japan, Australia, Indonesia, the Philippines, India and Thailand. Equis Energy invests in countries with favourable regulatory regimes and supportive power market dynamics.  As of today, Equis Energy has developed a portfolio of 1.9 GW of operational, construction and shovel-ready solar PV and onshore wind assets.  In addition, Equis Energy owns a promising long-term development pipeline comprised of over 115 projects representing 9.1 GW.

Equis Energy places a strong emphasis on building strong management capabilities in each country.  It employs over 300 dedicated professionals with industry-leading sector expertise. Its management capabilities span the entire renewable project value chain: origination, permitting, design, procurement, construction, financing and operations. Since its inception in 2012, Equis Energy has organically developed and built 100 percent of its portfolio. The company is focused on retaining full control of its projects, which has resulted in superior speed of execution and an enhanced success rate for its development projects. This operating strategy has driven the strong growth of the platform. The operating assets generate stable earnings, which are underpinned by fixed, long-term offtake agreements.

The Equis Energy Transaction is subject to customary regulatory closing conditions, and is expected to close in the first quarter of 2018.

Adebayo Ogunlesi, Chairman and Managing Partner of GIP said: "We are excited by the new investment in Equis Energy which is a strong fit with GIP's global renewable investment strategy. Equis Energy is a unique success story in the APAC region as it has systematically executed its growth strategy since its founding five years ago. In that period, Equis Energy has become one of the leading renewable energy platforms in the region, with a best-in-class business model, a high-quality asset portfolio and an outstanding management team. We look forward to continuing the Equis Energy success story in the years to come and to supporting new growth opportunities in one of the most promising renewable energy markets in the world."


About Global Infrastructure Partners

GIP is an independent infrastructure fund manager that combines deep industry expertise with industrial best practice operational management. GIP's current equity fund, Global Infrastructure Partners III, makes equity investments in high quality infrastructure assets in the energy, transport and water/waste sectors where GIP possesses deep experience and strong relationships.

For more information, visit www.global-infra.com 

About PSP Investments

PSP Investments is one of Canada's largest pension investment managers with C$135.6 billion of net assets under management as at March 31, 2017. It manages a diversified global portfolio composed of investments in public financial markets, private equity, real estate, infrastructure, natural resources and private debt.

PSP Investments is committed to renewable energy, with six direct investments and net owned capacity of approximately 3 GW. Its investment strategy in the renewables space complements its diversified global portfolio, adding the potential for increased returns with decreased risk, and a lower carbon footprint.

For more information, visit www.investpsp.com

About CIC Capital

CIC Capital, a wholly-owned direct subsidiary of China Investment Corporation ("CIC"), was incorporated in January 2015 with a mandate to specialise in making direct investments to refine CIC's overall portfolio management and enhance investment on long-term assets. As CIC's direct investment arm, CIC Capital is mandated to make direct investments and manage bilateral and multilateral fund investment in order to pursue long-term returns and promote international investment cooperation. CIC Capital is a market-oriented commercial entity with a specialised mandate and global reach.

For more information, visit www.china-inv.cn

Jack Cowell
Global Infrastructure Partners
212 315 8133
Jack.Cowell@global-infra.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Global Infrastructure Partners via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29Pressmeddelande

Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre

Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30Pressmeddelande

SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be

Corline Biomedical AB: Corline erhåller andra utbetalningen från EU-kommissionen31.7.2018 08:45Pressmeddelande

Corline Biomedical AB ("Corline") meddelade i november 2016 att EU-kommissionen beslutat anslå ca 2,4 MEUR (ca 23,1 MSEK) till bolagets kliniska studie inom njurtransplantation med läkemedelskandidaten Renaparin ® . En första utbetalning från H2020-programmet till Corline om ca 1,2 MEUR genomfördes i mars 2017. Corline har nu sammanställt en rapport till EU-kommissionen i vilken framgår att samtliga delmål i projektets första fas är uppnådda. Därmed har kommissionen beslutat om fortsatt stöd och en andra delbetalning om ca 1 MEUR utbetalas inom kort. Corline erhåller anslaget för att genomföra den planerade kliniska fas 1-studien för Renaparin® som är under utveckling för att förbättra njurtransplantation. Den första projektfasen har bland annat innefattat GMP-produktion av läkemedelssubstansen och upprättande av ansökan om klinisk prövning samt inlämnande av densamma till Läkemedelsverket. Samtliga delmål i den första projektfasen har uppfyllts och rapporteringen om dessa har nu grans

RFA Accelerates Growth with Expansion in Luxembourg30.7.2018 15:00Pressmeddelande

RFA announces new private financial cloud in Luxembourg to accelerate growth and accommodate increased demand in technology regulation and cybersecurity LUXEMBOURG, July 30, 2018 (GLOBE NEWSWIRE) -- RFA, a next-gen managed IT service provider for the financial industry, announces a new private financial cloud in Luxembourg. This expansion allows RFA to accommodate accelerated growth in Europe and offer a portfolio of high quality private cloud services to both its existing and new financial services clients in Luxembourg, Madrid, Paris, and the wider region. Along with the London office, the new office doubles RFA's footprint in Europe and further bolsters the company's growth strategy. RFA has two highly secure, tier-one data centres in Luxembourg which meet the ISO27001 and SSAE16/Type II standards, which is key for firms regulated by the Commission de Surveillance du Sector Financier (CSSF). RFA is now ideally placed to provide a range of services to clients in this region, and offe

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum